Volcano Corp. buys Crux Biomedical

The same month it netted $445.3mm through a notes offering, Volcano Corp. has agreed to buy closely held minimally invasive cardiovascular device company Crux Biomedical Inc. for $36mm in cash, up to $3.1mm in transaction expenses, and earn-outs, including $3mm if the company gets 510(k) approval by June 30, 2013 for a retrieval device in development. Crux shareholders may receive additional cash payments based on sales (for up to four years post-commercialization).